&nbsp;

olsp-postcard-other-languages.zip

New

Sep 2025

Document

olsp-poster-other-languages.zip

New

Sep 2025

Document

olsp-fact-sheet-other-languages.zip

New

Sep 2025

Document

olsp-fact-sheet-2025-fr.pdf

New

Sep 2025

Document

olsp-fact-sheet-2025.pdf

New

Sep 2025

Drug

belzutifan

Other Name(s): Welireg®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Updated

Sep 2025

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Updated

Sep 2025

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Palliative

Funding:

New Drug Funding Program

Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

New Drug Funding Program

Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)

Drugs Used:

blinatumomab

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative

Funding:

New Drug Funding Program

Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia

Drugs Used:

blinatumomab

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative, Palliative

Drugs Used:

blinatumomab (Compassionate)

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

BORTDEXADARA(SC)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

New Drug Funding Program

Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (subcut),

bortezomib,

dexamethasone